Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results

Abstract

BackgroundFew studies have formally assessed whether treatment outcomes have improved substantially over the years for patients with extensive disease small-cell lung cancer (ED-SCLC) enrolled in phase III trials. The objective of the current investigation was to determine the time trends in outcomes for the patients in those trials.Methods and FindingsWe searched for trials that were reported between January 1981 and August 2008. Phase III randomized controlled trials were eligible if they compared first-line, systemic chemotherapy for ED-SCLC. Data were evaluated by using a linear regression analysis. Results: In total, 52 trials were identified that had been initiated between 1980 and 2006; these studies involved 10,262 patients with 110 chemotherapy arms. The number of randomized patients and the proportion of patients with good performance status (PS) increased over time. Cisplatin-based regimens, especially cisplatin and etoposide (PE) regimen, have increasingly been studied, whereas cyclophosphamide, doxorubicin, and vincristine–based regimens have been less investigated. Multiple regression analysis showed no significant improvement in survival over the years. Additionally, the use of a PE regimen did not affect survival, whereas the proportion of patients with good PS and the trial design of assigning prophylactic cranial irradiation were significantly associated with favorable outcome.Conclusions and SignificanceThe survival of patients with ED-SCLC enrolled in phase III trials did not improve significantly over the years, suggesting the need for further development of novel targets, newer agents, and comprehensive patient care.

Targeting Small Cell Lung Cancer Harboring PIK3CA Mutation with a Selective Oral PI3K Inhibitor PF-4989216

“…Cells (25,,000 cells/well) were seeded in a 96-well microtiter plate and cultured overnight. The next day, PF-4989216 was added to each well starting at 10 mmol/L with a 3-fold serial dilution for 2 hours.…”

“…Response to second-line chemotherapy for patients with refractory disease is less than 10%, and survival is 3 to 4 months (22,23). Multiple phase III trials have been conducted; however, the survival of patients with SCLC has not improved significantly over the years (24,25). Therefore, a targeted therapeutic approach is in strong demand for patients with SCLC.…”

Anthrax toxin receptor 1 is the cellular receptor for Seneca Valley virus

“…SCLC is a highly aggressive and nearly universally lethal cancer, for which few tractable therapeutic targets have been identified. Many large-scale clinical trials, conducted without biomarker selection, have failed to advance the standard of care for this disease (42,43). Carefully defined biomarkers that would focus novel therapeutic studies on the potentially responsive subset of patients could change this field.…”

Endosialin: A novel malignant cell therapeutic target for neuroblastoma

“…Small cell lung cancer is initially very responsive to chemotherapy; however, most patients relapse and die within 2 years (17). A recent review of nearly three decades of small cell lung cancer phase III clinical trials for extensive disease involving over 10,000 patients found no significant improvement in patient survival times over that period of time (23).…”